Bioactive pea protein hydrolysate: pilot plant scale-up and beverage formulation (Phase 1)

生物活性豌豆蛋白水解物：中试工厂规模扩大和饮料配方（第一阶段）

• 批准号: 428620-2012
• 负责人: Aluko, Rotimi
• 金额: $ 8.6万
• 依托单位: University of Manitoba
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=499044
• 关键词: Bioactive; pea; protein; hydrolysate; pilot

Our previous work has isolated a bioactive pea protein hydrolysate (PPH) from the seeds of Canadian-grown yellow field peas. Oral administration to spontaneously hypertensive rats and human subjects reduced systolic blood pressure by up to 20 and 10 mmHg, respectively. Based on the animal and human studies we have concluded that the PPH is potential therapeutic agent against hypertension. In order to advance the PPH towards successful commercialization, we need to prove that it can be produced on large-scale suitable for technology transfer to the industry. Also, due to the potential bitter flavour of food protein hydrolysates, we must show that incorporation of the product into beverages can be optimized without reducing efficacy or potency of the product. Therefore, the objectives of the proposal are to develop a pilot plant scale-up method for producing PPH and to deetermine optimal levels of beverage formulations containing the PPH. Pilot plant scale-up will be performed by contract in one of the foremost industrial facilities with every step optimized for producing kilogram quantities of the product. Beverage (orange and apple juices) formulations that contain PPH at various levels will be tested for bitterness using a human sensory test panel in addition to an electronic tongue instrument. The PPH is unique when compared to existing antihypertensive drugs and natural products because of its ability to reduce activity of renin and cause reduction in blood pressure. Currently, only one

我们以前的工作已经分离出一个生物活性豌豆蛋白水解物（PPH）从种子的豌豆种植的黄色领域。自发性高血压大鼠和人类受试者经口给药分别使收缩压降低20和10 mmHg。基于动物和人体研究，我们得出结论，PPH是潜在的治疗高血压的药物。为了推动PPH走向成功的商业化，我们需要证明它可以大规模生产，适合向工业转移技术。此外，由于食品蛋白质水解物的潜在苦味，我们必须证明可以在不降低产品功效或效力的情况下优化将产品掺入饮料中。因此，该提案的目标是开发一种用于生产PPH的中试工厂放大方法，并确定含有PPH的饮料配方的最佳水平。中试工厂的规模扩大将通过合同在最重要的工业设施之一进行，每一步都经过优化，以生产千克数量的产品。除了电子舌仪器外，还将使用人类感官测试板测试含有不同水平PPH的饮料（橙子和苹果汁）配方的苦味。与现有的抗高血压药物和天然产品相比，PPH是独一无二的，因为它能够降低肾素活性并降低血压。目前，只有一个